Sawaf Aziz 4

What Happened

• Sawaf Aziz, Chief Financial Officer of Theravance Biopharma (TBPH), was reported to have received 37,500 shares on 2026-04-01. The Form 4 transaction is coded as an award/grant (code A) and shows an acquisition price of $0.00.

Key Details

• Transaction date: 2026-04-01
• Transaction type/code: Award/Grant (A)
• Shares acquired: 37,500
• Reported price: $0.00 (no purchase price)
• Filing date: 2026-04-03 (appears timely — within the two business-day Form 4 reporting window)
• Shares owned after transaction: Not specified in the provided details (see the full Form 4 for total beneficial ownership)
• No footnotes provided in the summary data (e.g., 10b5-1, tax withholding) — check the official filing for any explanatory notes

Context

• Awards and grants (often RSUs or similar equity compensation) are common forms of executive pay and do not necessarily signal a buy or sell decision by the insider. Because the acquisition price is $0.00, this reflects a grant/settlement rather than a market purchase. Retail investors should review the full Form 4 and related proxy or company disclosures for plan details and any transfer restrictions.